What is Aimei Health Technology Co Ltd's earnings per share (EPS)?

Aimei Health Technology Co Ltd (AFJK) reported diluted earnings per share of $0.17 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aimei Health Technology Co Ltd Financials

AFJK

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Aimei Health Technology Co Ltd (AFJK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AFJK FY2024 2026-05-04

Accounting profit diverged from cash reality as liquidity tightened and the balance sheet stayed creditor-funded in FY2024.

FY2024 shows a profit-quality split: net income was $2.6M even though operating income was -$1.1M and operating cash flow was -$672K. With cash falling from $581K to $28K, the reported profit did not fund the business, which usually means the gain came from non-operating or non-cash items rather than the core operation.

The company remained in a negative-equity position for two straight years, with liabilities exceeding assets by $134K in FY2023 and $1.5M in FY2024. That matters because the asset base is effectively financed by obligations, so additional losses deepen dependence on creditors instead of being absorbed by an equity cushion.

Current assets fell from $581K to $30K, which removed most of the near-term cash buffer. At the same time, current liabilities rose from $25K to $817K, leaving short-term obligations larger than readily available resources and making the business more dependent on external funding to bridge day-to-day needs.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Aimei Health Technology Co Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Aimei Health Technology Co Ltd's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

2/9

Aimei Health Technology Co Ltd passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

-0.53x

For every $1 of reported earnings, Aimei Health Technology Co Ltd generates $-0.53 in operating cash flow (-$565K OCF vs $1.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

$1.1M

YoY-58.5%

Aimei Health Technology Co Ltd reported $1.1M in net income in fiscal year 2025. This represents a decrease of 58.5% from the prior year.

EPS (Diluted)

$0.17

Aimei Health Technology Co Ltd earned $0.17 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3K

YoY-89.6%

Aimei Health Technology Co Ltd held $3K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+187.9%

Aimei Health Technology Co Ltd had 6M shares outstanding in fiscal year 2025. This represents an increase of 187.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

AFJK Income Statement

Metric	FY25	FY24	FY23
Revenue	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A
SG&A Expenses	$10K	N/A	N/A
Operating Income	-$836K+21.5%	-$1.1M	N/A
Interest Expense	N/A	N/A	N/A
Income Tax	$0	$0	$0
Net Income	$1.1M-58.5%	$2.6M	N/A
EPS (Diluted)	$0.17	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	-$130K-212.8%	-$42K+89.9%	-$413K	N/A	-$200K+35.3%	-$309K-101.2%	-$154K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	N/A	$0	$0	$0
Net Income	N/A	$352K-17.2%	$425K+130.1%	$185K	N/A	$744K+22.1%	$609K-19.4%	$756K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AFJK Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$12.1M-83.6%	$73.8M+4.7%	$70.5M
Current Assets	$3K-90.4%	$30K-94.8%	$581K
Cash & Equivalents	$3K-89.6%	$28K-95.1%	$581K
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$16.2M-78.5%	$75.3M+6.6%	$70.6M
Current Liabilities	$3.4M+312.7%	$817K+3188.9%	$25K
Long-Term Debt	N/A	N/A	N/A
Total Equity	-$4.1M-174.9%	-$1.5M-1000.9%	-$134K
Retained Earnings	-$4.1M-174.8%	-$1.5M-999.3%	-$134K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$12.1M-73.4%	$45.5M+2.0%	$44.6M+2.2%	$43.6M-40.9%	$73.8M+1.4%	$72.8M+1.2%	$71.9M+0.9%	$71.3M
Current Assets	$3K-88.3%	$25K-44.1%	$45K+456.4%	$8K-73.6%	$30K-75.5%	$124K-39.4%	$204K-57.5%	$481K
Cash & Equivalents	$3K-1.7%	$3K+39.3%	$2K-70.9%	$7K-74.0%	$28K-72.8%	$104K-34.3%	$158K-61.9%	$414K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$16.2M-67.0%	$48.9M+3.1%	$47.4M+3.1%	$46.0M-38.9%	$75.3M+2.3%	$73.6M+1.5%	$72.5M+1.3%	$71.6M
Current Liabilities	$3.4M+21.5%	$2.8M+25.3%	$2.2M+31.3%	$1.7M+106.3%	$817K+254.0%	$231K+107.5%	$111K+41.7%	$78K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$4.1M-18.0%	-$3.4M-20.3%	-$2.9M-20.8%	-$2.4M-60.3%	-$1.5M-85.3%	-$797K-33.5%	-$597K-107.4%	-$288K
Retained Earnings	-$4.1M-18.0%	-$3.4M-20.3%	-$2.9M-20.8%	-$2.4M-60.3%	-$1.5M-85.3%	-$797K-33.5%	-$597K-107.3%	-$288K

AFJK Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$565K+15.9%	-$672K	N/A
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	N/A	-$278K	N/A
Financing Cash Flow	N/A	$397K	N/A
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$43K+55.0%	-$96K+52.4%	-$202K+9.9%	-$224K-14.8%	-$195K-261.7%	-$54K+78.9%	-$256K-53.5%	-$167K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$33.7M+7587.1%	-$450K0.0%	-$450K-101.5%	$30.8M	N/A	N/A	N/A	N/A
Financing Cash Flow	-$33.6M-6252.1%	$547K-15.4%	$647K+102.1%	-$30.6M	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$34.1M	$0	$0-100.0%	$31.3M	N/A	N/A	N/A	N/A

AFJK Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A
Return on Assets	8.8%+5.3pp	3.5%	N/A
Current Ratio	0.00-0.0	0.04-23.3	23.38
Debt-to-Equity	N/A	-50.99+475.4	-526.41
FCF Margin	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	0.8%-0.2pp	0.9%+0.5pp	0.4%	N/A	1.0%+0.2pp	0.9%-0.2pp	1.1%
Current Ratio	0.000.0	0.01-0.0	0.02+0.0	0.00-0.0	0.04-0.5	0.54-1.3	1.84-4.3	6.13
Debt-to-Equity	-3.98+10.2	-14.22+2.4	-16.58+2.8	-19.42+31.6	-50.99+41.3	-92.34+29.2	-121.50+127.2	-248.71
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$4.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Cayson Acquisition Corp CAPN

$58.2M

Rising Dragon RDAC

$50.9M

Eureka Acquisition Corp EURKU

FLAG SHIP ACQUISITION CORP FSHPU

DT Cloud Star Acquisition Corporation DTSQU

Frequently Asked Questions

Is Aimei Health Technology Co Ltd profitable?

Yes, Aimei Health Technology Co Ltd (AFJK) reported a net income of $1.1M in fiscal year 2025.

What is Aimei Health Technology Co Ltd's operating cash flow?

Aimei Health Technology Co Ltd (AFJK) generated -$565K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aimei Health Technology Co Ltd's total assets?

Aimei Health Technology Co Ltd (AFJK) had $12.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Aimei Health Technology Co Ltd have outstanding?

Aimei Health Technology Co Ltd (AFJK) had 6M shares outstanding as of fiscal year 2025.

What is Aimei Health Technology Co Ltd's current ratio?

Aimei Health Technology Co Ltd (AFJK) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Aimei Health Technology Co Ltd's return on assets (ROA)?

Aimei Health Technology Co Ltd (AFJK) had a return on assets of 8.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aimei Health Technology Co Ltd's cash runway?

Based on fiscal year 2025 data, Aimei Health Technology Co Ltd (AFJK) had $3K in cash against an annual operating cash burn of $565K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Aimei Health Technology Co Ltd's Piotroski F-Score?

Aimei Health Technology Co Ltd (AFJK) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aimei Health Technology Co Ltd's earnings high quality?

Aimei Health Technology Co Ltd (AFJK) has an earnings quality ratio of -0.53x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Aimei Health Technology Co Ltd?

Aimei Health Technology Co Ltd (AFJK) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.